Merus (NASDAQ:MRUS) Major Shareholder A/S Genmab Purchases 15,710 Shares

December 30, 2025 by InsiderTrades.com

Key Points

A/S Genmab executed multiple purchases of Merus shares in mid‑late December (including 96,082 shares on Dec. 24 at $97), and after that trade owned 72,685,899 shares valued at about $7.05 billion.
Across the Dec. 16–26 trades listed, Genmab bought roughly 1.37 million shares at about $97 each, totaling approximately $132.5 million, signaling significant insider accumulation.
Merus stock opened at $90 (down 7.1%), with a 12‑month range of $33.19–$97.14 and a market cap of $6.83 billion; analyst consensus is a Hold rating with an average price target of about $93.56.

Merus N.V. (NASDAQ:MRUS - Get Free Report) major shareholder A/S Genmab acquired 15,710 shares of the stock in a transaction dated Monday, December 22nd. The stock was acquired at an average cost of $97.00 per share, with a total value of $1,523,870.00. Following the completion of the transaction, the insider owned 72,028,775 shares in the company, valued at approximately $6,986,791,175. This represents a 0.02% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.

A/S Genmab also recently made the following trade(s):

On Friday, December 26th, A/S Genmab bought 142,610 shares of Merus stock. The shares were acquired at an average price of $97.00 per share, for a total transaction of $13,833,170.00.
On Wednesday, December 24th, A/S Genmab bought 96,082 shares of Merus stock. The stock was acquired at an average price of $97.00 per share, with a total value of $9,319,954.00.
On Tuesday, December 23rd, A/S Genmab purchased 561,042 shares of Merus stock. The stock was acquired at an average cost of $97.00 per share, for a total transaction of $54,421,074.00.
On Friday, December 19th, A/S Genmab acquired 66,264 shares of Merus stock. The shares were bought at an average cost of $97.00 per share, with a total value of $6,427,608.00.
On Thursday, December 18th, A/S Genmab acquired 212,177 shares of Merus stock. The stock was bought at an average price of $97.00 per share, with a total value of $20,581,169.00.
On Wednesday, December 17th, A/S Genmab bought 150,795 shares of Merus stock. The shares were bought at an average price of $97.00 per share, for a total transaction of $14,627,115.00.
On Tuesday, December 16th, A/S Genmab bought 120,752 shares of Merus stock. The shares were bought at an average cost of $97.00 per share, for a total transaction of $11,712,944.00.

Merus Trading Down 7.1%

NASDAQ:MRUS opened at $90.00 on Tuesday. Merus N.V. has a 12 month low of $33.19 and a 12 month high of $97.14. The stock has a market capitalization of $6.83 billion, a price-to-earnings ratio of -16.98 and a beta of 1.06. The firm has a fifty day simple moving average of $95.78 and a two-hundred day simple moving average of $77.75.

Hedge Funds Weigh In On Merus

Large investors have recently bought and sold shares of the stock. Paradigm Biocapital Advisors LP boosted its holdings in Merus by 99.4% during the 1st quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company's stock worth $141,831,000 after acquiring an additional 1,679,777 shares during the last quarter. Magnetar Financial LLC purchased a new position in Merus during the third quarter worth about $98,406,000. Ameriprise Financial Inc. boosted its holdings in Merus by 1,007.3% during the second quarter. Ameriprise Financial Inc. now owns 1,133,857 shares of the biotechnology company's stock worth $59,641,000 after purchasing an additional 1,031,457 shares during the last quarter. Pentwater Capital Management LP bought a new stake in Merus in the 3rd quarter worth about $91,326,000. Finally, Alpine Associates Management Inc. purchased a new stake in Merus in the 3rd quarter valued at about $78,672,000. 96.14% of the stock is currently owned by institutional investors.

Trending Headlines about Merus

Here are the key news stories impacting Merus this week:

Positive Sentiment: Major shareholder A/S Genmab executed multiple, sizable purchases of Merus stock on Dec. 22–26 (totaling >815,000 shares at an average of $97.00), nudging its ownership higher and signaling continued insider confidence in the company. Institutional buying at these sizes can be a bullish signal for longer‑term holders. SEC Ownership Filing
Neutral Sentiment: Unusually large options activity was reported in Merus recently; such flows can reflect speculative trading, hedging by institutional players, or positioning ahead of news/events — this increases near‑term volatility but is ambiguous for direction. Merus Target of Unusually Large Options Trading

Analysts Set New Price Targets

Several brokerages have issued reports on MRUS. Barclays reiterated an "equal weight" rating and issued a $97.00 price target (down previously from $112.00) on shares of Merus in a report on Tuesday, September 30th. Leerink Partners reiterated a "market perform" rating and issued a $97.00 target price (up from $95.00) on shares of Merus in a report on Monday, October 6th. UBS Group downgraded shares of Merus from a "buy" rating to a "neutral" rating and lifted their price target for the company from $72.00 to $97.00 in a research report on Tuesday, September 30th. Canaccord Genuity Group downgraded shares of Merus from a "buy" rating to a "hold" rating and upped their price objective for the stock from $67.00 to $97.00 in a report on Monday, September 29th. Finally, Leerink Partnrs lowered shares of Merus from a "strong-buy" rating to a "hold" rating in a research note on Sunday, October 5th. Three equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $93.56.

View Our Latest Report on Merus

About Merus

(Get Free Report)

Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company's research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.

The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development.